Achieve Life Sciences (ACHV) Current Deferred Revenue (2010 - 2016)

Achieve Life Sciences (ACHV) posted Current Deferred Revenue of $2.1 million for Q1 2016, down 58.35% on a QoQ basis from $5.0 million in Q4 2015.

Achieve Life Sciences (ACHV) Current Deferred Revenue (2010 - 2016) Analysis & Trends

Achieve Life Sciences' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $2.1 million for Q1 2016.

Quarterly Current Deferred Revenue changed N/A year-over-year to $2.1 million in Q1 2016, while the trailing twelve-month figure through Mar 2016 was $2.1 million (changed N/A YoY) and the FY2015 annual result came in at $5.0 million, changed N/A from the prior year.
Current Deferred Revenue was $2.1 million for Q1 2016 at Achieve Life Sciences, down from $5.0 million in the prior quarter.
Across five years, Current Deferred Revenue topped out at $17.8 million in Q2 2015 and bottomed at $2.1 million in Q1 2016.
A 3-year average of $11.1 million and a median of $11.0 million in 2015 frame the typical range for Current Deferred Revenue.
Peak annual rise in Current Deferred Revenue reached 53.72% in 2012, while the deepest fall reached 8.55% in 2012.
Achieve Life Sciences' Current Deferred Revenue stood at $9.1 million in 2012, then slumped by 44.89% to $5.0 million in 2015, then plunged by 58.35% to $2.1 million in 2016.
Business Quant data shows ACHV's Current Deferred Revenue at $2.1 million in Q1 2016, $5.0 million in Q4 2015, and $11.0 million in Q3 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Achieve Life Sciences	2.54 Mn	2.54 Mn	-

Download Data